MicroRNA‑19b inhibitors can attenuate the STAT3 signaling pathway in NPC C666‑1 cells

Bian,Li‑Hui; Duan,Jing‑Ling; Zhou,Chen; Shen,Guo‑Wen; Wang,Xiao‑Yu; Yang,Yang; Zhang,Xiao‑Ling; Xiao,Sheng‑Jun

doi:10.3892/mmr.2020.11112

MicroRNA‑19b inhibitors can attenuate the STAT3 signaling pathway in NPC C666‑1 cells

Authors:
- Li‑Hui Bian
- Jing‑Ling Duan
- Chen Zhou
- Guo‑Wen Shen
- Xiao‑Yu Wang
- Yang Yang
- Xiao‑Ling Zhang
- Sheng‑Jun Xiao
View Affiliations

Affiliations: Department of Pathology, The Second Affiliated Hospital, Guilin Medical University, Guilin, Guangxi 541199, P.R. China, Department of Pathology and Pathophysiology, Graduate School of Guilin Medical University, Guilin, Guangxi 541004, P.R. China, Department of Physiology, Faculty of Basic Medical Sciences, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
Published online on: May 4, 2020 https://doi.org/10.3892/mmr.2020.11112
Pages: 51-56
Copyright: © Bian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-19b is expressed in various types of tumors and may serve as a potential therapeutic target. The miR‑17‑92 cluster is upregulated in nasopharyngeal carcinoma (NPC) tissues and cells. miR‑19b is a member of the miR‑17‑92 cluster; however, its expression and function in NPC are largely unknown. The present study aimed to investigate the expression and function of miR‑19b in NPC cells. The miRCURY LNATM miRNA Inhibitor (miR‑19b inhibitor and negative control) were transfected into C666‑1 cells. The proliferation, apoptosis and migration of the cells were subsequently detected by the Cell Counting Kit‑8 assay, flow cytometry and Transwell assay, respectively. Additionally, the expression of STAT3 signaling pathway‑associated proteins [STAT3, pSTAT3 and suppressor of cytokine signaling 1 (SOCS1)] and the transcriptional targets of pSTAT3 [Bcl‑2, myeloid leukemia protein 1 (Mcl‑1) and cyclin D1] were detected by western blotting. The miR‑19b inhibitor inhibited proliferation and migration and induced apoptosis of C666‑1 cells. Furthermore, the miR‑19b inhibitor upregulated the expression of SOCS1, a predicted target gene of miR‑19b, and decreased the phosphorylation of STAT3 at Tyr705 and Ser727. These data indicated that upregulation of SOCS1, an endogenous inhibitor of STAT3 phosphorylation, attenuated the STAT3 signaling pathway in C666‑1 cells. Moreover, the expression level of the proproliferative protein cyclin D1 and antiapoptotic proteins Mcl‑1 and Bcl‑2 was significantly decreased following transfection with the miR‑19b inhibitor. The aforementioned three proteins are downstream transcriptional targets of the activated STAT3 signaling pathway. The results of the present study revealed that inhibition of miR‑19b negatively modulated the malignant behavior of NPC cells via the STAT3 signaling pathway. Therefore, miR‑19b inhibition may serve as a novel therapeutic target for the treatment of NPC.

View Figures

View References

1	Chua MLK, Wee JTS, Hui EP and Chan ATC: Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
2	Prawira A, Oosting SF, Chen TW, Delos Santos KA, Saluja R, Wang L, Siu LL, Chan KKW and Hansen AR: Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: A systematic review. Br J Cancer. 117:1743–1752. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chen Y, Gao DY and Huang L: In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
7	Braicu C, Calin GA and Berindan-Neagoe I: MicroRNAs and cancer therapy-from bystanders to major players. Curr Med Chem. 20:3561–3573. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, et al: MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest. 95:1056–1070. 2015. View Article : Google Scholar : PubMed/NCBI
9	Li C, Zhang J, Ma Z, Zhang F and Yu W: miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 11:4087–4095. 2018. View Article : Google Scholar : PubMed/NCBI
10	Vij N, Sharma A, Thakkar M, Sinha S and Mohan RR: PDGF-driven proliferation, migration, and IL8 chemokine secretion in human corneal fibroblasts involve JAK2-STAT3 signaling pathway. Mol Vis. 14:1020–1027. 2008.PubMed/NCBI
11	Ma F, Wang Z, Wang J, Liu X and Hu C: MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2. Exp Ther Med. 14:1419–1426. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hsu CY, Yi YH, Chang KP, Chang YS, Chen SJ and Chen HC: The epstein-barr virus-encoded MicroRNA MiR-BART9 Promotes Tumor Metastasis by Targeting E-Cadherin in nasopharyngeal carcinoma. PLoS Pathog. 10:e10039742014. View Article : Google Scholar : PubMed/NCBI
13	Lin TY, Chen Y, Jia JS, Zhou C, Lian M, Wen YT, Li XY, Chen HW, Lin XL, Zhang XL, et al: Loss of Cirbp expression is correlated with the malignant progression and poor prognosis in nasopharyngeal carcinoma. Cancer Manag Res. 11:6959–6969. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q, Luo X, Chen Y, Deng X, Liang Z, et al: MiR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 7:11309–11322. 2016. View Article : Google Scholar : PubMed/NCBI
15	Li X, Zhao Z, Zhang X, Yang S, Lin X, Yang X, Lin X, Shi J, Wang S, Zhao W, et al: Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharygeal carcinoma. Oncotarget. 8:93924–93941. 2017. View Article : Google Scholar : PubMed/NCBI
16	Xiao K, Yu Z, Li X, Li X, Tang K, Tu C, Qi P, Liao Q, Chen P, Zeng Z, et al: Genome-wide analysis of epstein-barr virus (EBV) integration and strain in C666-1 and raji cells. J Cancer. 7:214–224. 2016. View Article : Google Scholar : PubMed/NCBI
17	Davey GM, Heath WR and Starr R: SOCS1: A potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 67:1–9. 2006. View Article : Google Scholar : PubMed/NCBI
18	Liu M, Yang R, Urrehman U, Ye C, Yan X, Cui S, Hong Y, Gu Y, Liu Y, Zhao C, et al: MiR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget. 7:64100–64108. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wang H, Xiong M, Hu Y, Sun Y and Ma Q: MicroRNA-19b inhibits proliferation of gastric cancer cells by targeting B-cell CLL/lymphoma 3. Oncol Rep. 36:2079–2086. 2016. View Article : Google Scholar : PubMed/NCBI
20	Li X, Wang FS, Wu ZY, Lin JL, Lan WB and Lin JH: MicroRNA-19b targets Mfn1 to inhibit Mfn1-induced apoptosis in osteosarcoma cells. Neoplasma. 61:265–273. 2014. View Article : Google Scholar : PubMed/NCBI
21	Fan Y, Yin S, Hao Y, Yang J, Zhang H, Sun C, Ma M, Chang Q and Xi JJ: miR-19b promotes tumor growth and metastasis via targeting TP53. RNA. 20:765–772. 2014. View Article : Google Scholar : PubMed/NCBI
22	Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang J, McCarthy JB, She X, Zhang W, Ma J, et al: MiR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cheng GZ, Zhang W, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ and Wang LH: Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 283:14665–14673. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ferguson SD, Srinivasan VM and Heimberger AB: The role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 123:385–394. 2015. View Article : Google Scholar : PubMed/NCBI
25	Teng Y, Ross JL and Cowell JK: The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
26	Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To KF, Hayward DS, Chui YL, Lau YL, Takada K and Huang DP: Epstein-barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia. 8:173–180. 2006. View Article : Google Scholar : PubMed/NCBI
27	Ho Y, Tsao SW, Zeng M and Lui VW: STAT3 as a therapeutic target for Epstein-Barr virus (EBV): Associated nasopharyngeal carcinoma. Cancer Lett. 330:141–149. 2013. View Article : Google Scholar : PubMed/NCBI
28	Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al: Structure and functionof a new STAT-induced STAT inhibitor. Nature. 387:924–929. 1997. View Article : Google Scholar : PubMed/NCBI
29	Hamanaka I, Saito Y, Yasukawa H, Kishimoto I, Kuwahara K, Miyamoto Y, Harada M, Ogawa E, Kajiyama N, Takahashi N, et al: Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo. Circ Res. 88:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
30	Ben-Zvi T, Yayon A, Gertler A and Monsonego-Ornan E: Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci. 2:380–387. 2006. View Article : Google Scholar
31	Mignacca L, Saint-Germain E, Benoit A, Bourdeau V, Moro A and Ferbeyre G: Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine. 82:80–86. 2016. View Article : Google Scholar : PubMed/NCBI
32	Huang TQ, Willis MS and Meissner G: IL-6/STAT3 signaling in mice with dysfunctional type-2 ryanodine receptor. JAKSTAT. 4:e11583792016.PubMed/NCBI
33	Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J and Stark GR: STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci USA. 110:16975–16980. 2013. View Article : Google Scholar : PubMed/NCBI
34	Parys JB: The multifaceted STAT3: How a transcription factor regulates Ca²⁺ signaling via a degradative pathway. Cell Calcium. 76:137–139. 2018. View Article : Google Scholar : PubMed/NCBI
35	Yokogami K, Wakisaka S, Avruch J and Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol. 10:47–50. 2000. View Article : Google Scholar : PubMed/NCBI
36	Banerjee K and Resat H: Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 138:2570–2578. 2016. View Article : Google Scholar : PubMed/NCBI
37	Pardee AB: G1 events and regulation of cell proliferation. Science. 246:603–608. 1989. View Article : Google Scholar : PubMed/NCBI
38	Lam M, Dubyak G, Chen L, Nuñez G, Miesfeld RL and Distelhorst CW: Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA. 91:6569–6573. 1994. View Article : Google Scholar : PubMed/NCBI
39	Liu Q and Gehring K: Heterodimerization of BAK and MCL-1 Activated by Detergent Micelles. J Biol Chem. 285:41202–41210. 2010. View Article : Google Scholar : PubMed/NCBI